Meeting Coverage:

American Academy of Ophthalmology

AAO: 2018

Takeaways From New STAIRWAY Study Data

Show Description +

Arshad Khanani, MD, shares results of the phase 2 STAIRWAY study, a randomized study comparing extended 16-week and 12-week dosing of faricimab (formerly RG7716, Genentech) in patients with neovascular age-related macular degeneration with ranibizumab dosed every 4 weeks.

Posted: 10/28/2018

Up Next

Refractive Residencies

George O. Waring IV, MD, FACS , Osama Ibrahim, MD, Renato Ambrosio Jr, MD, PhD


Take-Home Points for APL-2

David S. Boyer, MD

Customizing the IOL

George O. Waring IV, MD, FACS

Anatomy in HAWK and HARRIER

Pravin U. Dugel, MD

New IOL Technologies

Amr M. Kouchouk, MD, Kendall E. Donaldson, MD, MS, Vance M. Thompson, MD, FACS

Topical Retina Treatments

Carl D. Regillo, MD, FACS, Caroline R. Baumal, MD, Michael A. Singer, MD

Takeaways From New STAIRWAY Study Data

Arshad Khanani, MD, shares results of the phase 2 STAIRWAY study, a randomized study comparing extended 16-week and 12-week dosing of faricimab (formerly RG7716, Genentech) in patients with neovascular age-related macular degeneration with ranibizumab dosed every 4 weeks.

Posted: 10/28/2018


Please log in to leave a comment.

More From AAO: 2018 Coverage